Picture of Orchestra Biomed Holdings logo

OBIO Orchestra Biomed Holdings Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m+19.38%
3m-29.2%
6m+13.57%
1yr-10.84%
Volume Change (%)
10d/3m-63.84%
Price vs... (%)
52w High-51.58%
50d MA+2.21%
200d MA-8.83%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-102.69%
Return on Equity-83.22%
Operating Margin-2858.97%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Orchestra Biomed Holdings EPS forecast chart

Profile Summary

Orchestra BioMed Holdings, Inc. is a biomedical innovation company. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. It is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. It is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    June 30th, 2024
    Incorporated
    January 25th, 2023
    Public Since
    August 4th, 2020
    No. of Shareholders
    595
    No. of Employees
    56
    Sector
    Healthcare Equipment & Supplies
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Market
    Shares in Issue
    37,824,571
    Blurred out image of a map
    Address
    150 Union Square Drive, NEW HOPE, 18938
    Web
    Phone
    +1 6463439298
    Auditors
    Ernst & Young LLP

    OBIO Share Price Performance

    Upcoming Events for OBIO

    Similar to OBIO

    Picture of 908 Devices. logo

    908 Devices.

    us flag iconNASDAQ Global Market

    Picture of Alpha Teknova logo

    Alpha Teknova

    us flag iconNASDAQ Global Market

    Picture of AtriCure logo

    AtriCure

    us flag iconNASDAQ Global Market

    Picture of Brainsway logo

    Brainsway

    us flag iconNASDAQ Global Market

    Picture of Castle Biosciences logo

    Castle Biosciences

    us flag iconNASDAQ Global Market

    FAQ